Suture line administration technique using botulinum toxins
The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
1. A method for treating a patient suffering from a headache, comprising the step of administering a therapeutically effective dose of a Clostridial toxin in the vicinity of at least one suture line of the patient's skull, wherein the administration alleviates at least one symptom of the headache, wherein the therapeutically effective dose of the Clostridial toxin administered is lower than a therapeutically effective dose required for administration to a muscle or a subcutaneous tissue of the face and head, thereby treating the patient suffering from the headache.
2. The method according to claim 1 , wherein the Clostridial neurotoxin is a botulinum toxin.
3. The method according to claim 1 , wherein the headache is selected from the group consisting of a sinus headache, a tension headache, a migraine headache, a cluster headache and a cervicogenic headache.
4. The method according to claim 1 , wherein the at least one suture line is selected from the group consisting of frontal suture, squamous suture, occipitomastoid suture, coronal suture, lambdoid suture and sagittal suture.
5. The method according to claim 2 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C 1 , D, E, F and G.
6. The method according to claim 5 , wherein the botulinum toxin is a botulinum toxin type A.
7. The method according to claim 6 , wherein the therapeutically effective dose of the botulinum toxin type A administered is from about 5 units to about 1000 units.
8. The method according to claim 1 , wherein the headache is an episodic migraine or a chronic migraine.
9. The method of claim 1 , further comprising the step of administering the Clostridial toxin in the vicinity of a second suture line.
10. The method of claim 1 , wherein the Clostridial neurotoxin is administered at about 1.5 cm, about 1.0 cm, or about 0.5 cm from the at least one suture line.
11. A method for alleviating a headache pain, comprising the step of determining the location of at least one suture line; and administering a therapeutically effective amount of a botulinum toxin type A to a patient in need thereof, wherein the botulinum toxin type A is administered in the vicinity of the at least one suture line of the patient's skull, wherein the therapeutically effective amount of the botulinum toxin type A administered is lower than a therapeutically effective amount required for administration to a muscle or a subcutaneous tissue of the face and head, thereby alleviating the headache pain.
12. The method of claim 11 , wherein the botulinum toxin type A is onabotulinumtoxinA.
13. The method of claim 12 , wherein the therapeutically effective amount of the administered botulinum toxin type A is from about 60 units to about 100 units.
14. The method according to claim 11 , wherein the at least one suture is selected from the group consisting of frontal suture, squamous suture, coronal suture, lambdoid suture, occipitomastoid suture and sagittal suture.
15. The method of claim 11 , wherein the administration step includes the step of inserting a needle of a syringe containing the botulinum toxin type A at a needle penetration point and positioning the needle along the at least one suture line so that the botulinum toxin type A is administered linearly along at least a portion of the at least one suture line.
16. A method for reducing adverse effects associated with the administration of a Clostridial toxin for treating or alleviating a headache in a patient in need thereof, the method comprises administering a therapeutically effective amount of a Clostridial toxin in the vicinity of at least one suture line of the patient's skull, wherein the therapeutically effective amount of the Clostridial toxin administered is lower than a therapeutically effective amount required for administration to a muscle or a subcutaneous tissue of the face and head.
17. The method of claim 16 , wherein the adverse effects comprise muscle weakness.
18. The method of claim 16 , wherein the Clostridial neurotoxin is a botulinum toxin.
19. The method according to claim 16 , wherein the headache is selected from the group consisting of a sinus headache, a tension headache, a migraine headache, a cluster headache and a cervicogenic headache.
20. The method according to claim 16 , wherein the at least one suture line is selected from the group consisting of frontal suture, squamous suture, occipitomastoid suture, coronal suture, lambdoid suture and sagittal suture.